Navigation Links
New antibiotic drug combo to speed up treatment of tuberculosis
Date:9/18/2007

A team of tuberculosis (TB) experts at Johns Hopkins and in Brazil have evidence that substituting the antibiotic moxifloxacin in the regimen of drugs used to treat the highly contagious form of lung disease could dramatically shorten the time needed to cure the illness from six months to four.

Adding moxifloxacin to a standard combination of other antibiotics increased by 17 percent the number of patients who cleared active infections from their lungs (raising cure rates from 68 percent to 85 percent), after just two months of therapy, and when compared to patients taking the standard combination with another, older antibiotic, ethambutol.

This is the most compelling evidence in nearly 25 years that a novel antibiotic drug combination works better than the current gold standard at curing active TB infection, says study senior author Richard E. Chaisson, M.D., a professor of medicine, epidemiology and international health at The Johns Hopkins University School of Medicine and founding director of its Center for Tuberculosis Research. Chaisson will present his teams findings Sept. 18 in Chicago at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Beyond the obvious value of healing patients more quickly, a shorter treatment time could also cut down on transmission of the disease to others and make it easier for health care workers worldwide, who are overwhelmed by large numbers of patients, to treat more people and to treat them faster, says Chaisson, who started the study in 2003.

He notes that worldwide, each year, nearly 9 million new cases of TB are diagnosed, and more than one and a half million people die from the disease, caused by Mycobacterium tuberculosis.

TB also remains the leading cause of death worldwide among those with HIV and AIDS and is epidemic in developing countries with the highest HIV-infection rates.

The new study of more than 170 men and wo
'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
2. Antibiotics Helps Autism
3. New antibiotic already developing resistance
4. Antibiotics losing their power against acne
5. Antibiotic induces liver damage in children with E.COLI infections.
6. Vaccine Reduces antibiotic-resistant infections in Children
7. Antibiotic from crab blood indentified
8. Gene clue to antibiotics
9. Excessive use of antibiotics for sore throat
10. E. coli strains resistant to a common antibiotic
11. Cost-effective antibiotics for sinusitis treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...e Royal Women's Hospital has found that the most c...nduced labor.// Nearly one-third of the women with... caesarians. The factors enhancing the risk of a C...st-time mothers. "The message we are taking is t...
... the University at Buffalo probing into the effect...fish as a model, have zeroed in on many proteins i...negatively with severe alcohol exposure. The scien... out after prolonged alcohol exposure, after they ...
...inister Anbumani Ramadoss has added a new twist to...angerous even without the added pesticides.// "Al...high-risk factors as much as tobacco and a compreh...ed," he said at the golden jubilee year celebratio...
...e University of South Florida College of Medicine ...in Florida is discouraging medical students// from...cialization. The situation means that many people ...n Deutsch, MD, lead author of the study and chief ...
Other Medicine News:Health News:Brain protein expression can be damaged with prolonged alcohol exposure 2Health News:Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology 2
(Date:7/23/2008)... WASHINGTON, July 23 /PRNewswire-USNewswire/ --... of Justice:, Chairman Conyers, Ranking Member Sm...he opportunity to testify today., Since I appeare...ave,become even better acquainted with the talente...tment and with the work they do, and I have come t...
(Date:7/23/2008)... ASPS Study Finds Some Areas of the Body Have G...IGHTS, Ill., July 23 /PRNewswire-USNewswire/ -- Fa...hrough liposuction was found to be,an excellent so...ations,than other areas of the body, reports a Bra...ructive Surgery(R), the official medical journal o...
(Date:7/23/2008)... SEATTLE, July 23 /- Den... that it expects the Independent Data,Monitoring C...rim analysis,of overall survival relating to the C...e AdenoCarcinoma Treatment, also known as D9902B) ...ENGE is the Company,s investigational,active cellu...
(Date:7/22/2008)... BRISBANE, Australia, July 22 /PRNewswire-First...d late yesterday, the Board of Progen,Pharmaceutic...ed that it,had discontinued the PI-88 phase 3 stud...direction to develop its existing portfolio of com...re additional compounds and,opportunities through ...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Looking at neurons from all sides 3069 1Looking at neurons from all sides 3069 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 1deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 5Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 1Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 1Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 9
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
...pany anticipates second quarter BLA filing for C1-... 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceutical...m,its pivotal U.S. Phase III trial of C1-esterase ...ditary angioedema (HAE). In the,acute study, which...tor in Hereditary Angioedema Nanofiltration Genera...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: